Image-based Re-evaluation of the JCOG0911 Study Focusing on Tumor Volume and Survival, Disease Progression Diagnosis, and Radiomic Prognostication for Newly Diagnosed Glioblastoma.

Autor:	Kinoshita M; Department of Neurosurgery, Asahikawa Medical University, Asahikawa, Hokkaido, Japan., Fushimi Y; Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan., Masumoto T; Department of Diagnostic Radiology, Toranomon Hospital, Tokyo, Japan., Sasaki K; JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan., Sekita T; JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan., Natsume A; The Institute of Innovation for Future Society, Nagoya University, Nagoya, Aichi, Japan., Wakabashi T; Department of Neurosurgery, Nagoya Garden Clinic, Nagoya, Aichi, Japan., Komori T; Department of Laboratory Medicine and Pathology (Neuropathology), Tokyo Metropolitan Neurological Hospital, Fuchu, Tokyo, Japan., Tsuzuki S; Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan., Muragaki Y; Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.; Center for Advanced Medical Engineering Research and Development, Kobe University, Kobe, Hyogo, Japan., Motomura K; Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan., Saito R; Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan., Sato K; Department of Neurosurgery, Nakamura Memorial Hospital, Sapporo, Hokkaido, Japan., Beppu T; Department of Neurosurgery, Iwate Medical University School of Medicine, Shiwa, Iwate, Japan., Takahashi M; Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan., Kuroda JI; Department of Neurosurgery, Kumamoto University, Kumamoto, Kumamoto, Japan., Sonoda Y; Department of Neurosurgery, Faculty of medicine, Yamagata University, Yamagata, Yamagata, Japan., Kobayashi K; Department of Neurosurgery, Kyorin University Faculty of Medicine, Mitaka, Tokyo, Japan., Mishima K; Department of Neuro-Oncology/Neurosurgery, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan., Mitsuya K; Division of Neurosurgery, Shizuoka Cancer Center, Sunto, Shizuoka, Japan., Yamasaki F; Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Hiroshima, Japan., Inoue A; Department of Neurosurgery, Ehime University Graduate School of Medicine, Toon, Ehime, Japan., Matsutani T; Department of Neurosurgery, Chiba University Graduate School of Medicine, Chiba, Chiba, Japan., Nakamura H; Department of Neurosurgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan., Yamaguchi S; Department of Neurosurgery, Hokkaido University, Sapporo, Hokkaido, Japan., Ishikawa E; Department of Neurosurgery, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan., Nakaya M; Department of Neurosurgery, Keio University School of Medicine, Tokyo, Japan., Tanaka S; Department of Neurosurgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Ujifuku K; Department of Neurosurgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan., Uchida H; Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Kagoshima, Japan., Kanamori M; Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan., Otani R; Department of Neurosurgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan., Kijima N; Department of Neurosurgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan., Nishida N; Department of Neurosurgery, Medical Research Institute Kitano Hospital, PIIF Tazuke-kofukai, Osaka, Osaka, Japan., Yoshino A; Department of Neurological Surgery, Nihon University School of Medicine, Tokyo, Japan., Mineharu Y; Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan., Arakawa Y; Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan., Fukuda H; JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan., Narita Y; Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan.
Jazyk:	angličtina
Zdroj:	Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine [Magn Reson Med Sci] 2024 Nov 19. Date of Electronic Publication: 2024 Nov 19.
DOI:	10.2463/mrms.mp.2024-0103
Abstrakt:	Purpose: To re-evaluate images recovered from JCOG0911, a randomized phase 2 trial for newly diagnosed glioblastoma (nGBM) conducted by the Japan Clinical Oncology Group (JCOG) Brain Tumor Study Group. Methods: The correlation between tumor volumes and survival was evaluated, followed by progression-free survival (PFS) analysis by independent central review based on Response Assessment in Neuro-Oncology (RANO) criteria using MRI recovered from 118 nGBM patients enrolled in the JCOG0911 trial. A radiomic analysis was also performed to identify radiomic features predictive of nGBM prognosis. Results: The distribution of the Gd-enhancing and T2-weighted image/fluid attenuated inversion recovery-high intensity lesions mainly occupied white matter. JCOG0911 consisted of more subjects with right-sided lesions. The median extent of resection of the Gd-enhancing lesions was 99%. The overall survival showed a nonsignificant negative trend with postoperative Gd-enhancing lesion volume (P = 0.22), with the hazard ratio increasing in parallel with its volume. The median PFS after registration was 302 and 308 days for local Response Evaluation Criteria in Solid Tumors (RECIST)-based and central RANO-based diagnoses. However, an apparent discrepancy was observed between the two in the early phase, presumably due to the misdiagnosis of pseudoprogression by local RECIST-based diagnosis. Radiomic analysis identified 28 radiomic features predictive of nGBM prognosis, 5 of which were those previously identified in a separate cohort. The constructed radiomics-based prognostic model stratified the cohort into high- and low-risk groups (P = 0.028). Conclusion: Novel analytical methods that could be incorporated into future clinical trials were successfully tested. RANO and RECIST may not differ in progression calls if pseudoprogression is appropriately handled.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu